Literature DB >> 8595405

Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.

G J Walker1, C J Hussussian, J F Flores, J M Glendening, F G Haluska, N C Dracopoli, N K Hayward, J W Fountain.   

Abstract

The cyclin dependent kinase inhibitor 2 (CDKN2) gene on chromosome 9p21 is potentially involved in the genesis of many cancers and is currently under intense investigation as a possible melanoma susceptibility locus. We have analyzed 18 Australian melanoma kindreds for mutations within the coding and neighboring splice junction portions of the CDKN2 gene. In seven kindreds (including our six largest), CDKN2 mutations were found to segregate with the putative melanoma chromosome previously assigned by 9p haplotype analysis. These changes included the duplication of a 24 bp repeat, a deleted C residue resulting in the introduction of a premature stop codon, and four single basepair changes causing amino acid substitutions. Mutations segregated to 46 of 51 affected individuals in these seven kindreds, with three apparent sporadic cases in one family and one in each of another two families. Penetrance was variable (55-100%) among the different mutations. These data provide additional strong support that the CDKN2 gene is the chromosome 9p21 familial melanoma locus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8595405     DOI: 10.1093/hmg/4.10.1845

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  20 in total

1.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

Review 2.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

3.  Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

Authors:  Miriam Potrony; Joan Anton Puig-Butillé; Paula Aguilera; Celia Badenas; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  J Am Acad Dermatol       Date:  2014-07-24       Impact factor: 11.527

4.  Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi.

Authors:  A M Goldstein; L R Goldin; N C Dracopoli; W H Clark; M A Tucker
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

5.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF.

Authors:  D E Quelle; M Cheng; R A Ashmun; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

6.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

7.  Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.

Authors:  M G FitzGerald; D P Harkin; S Silva-Arrieta; D J MacDonald; L C Lucchina; H Unsal; E O'Neill; J Koh; D M Finkelstein; K J Isselbacher; A J Sober; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

8.  A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families.

Authors:  P A van der Velden; L A Sandkuijl; W Bergman; E T Hille; R R Frants; N A Gruis
Journal:  Genome Res       Date:  1999-06       Impact factor: 9.043

9.  MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations.

Authors:  N F Box; D L Duffy; W Chen; M Stark; N G Martin; R A Sturm; N K Hayward
Journal:  Am J Hum Genet       Date:  2001-08-08       Impact factor: 11.025

10.  p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation.

Authors:  A Radfar; I Unnikrishnan; H W Lee; R A DePinho; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.